Startup profile for Gilgamesh Pharmaceuticals: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Gilgamesh Pharmaceuticals funding, valuation and investors

Neuropsychiatric drug development with a historical Ayuh Ventures investment.

Verified company research · funding, investors and latest developments

Keep track of Gilgamesh Pharmaceuticals

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Not publicly disclosed

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

Not publicly disclosed

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

Stage not recorded

Source links not recorded Last verified: 2026-11-15

Overview

Gilgamesh Pharmaceuticals develops investigational therapies for psychiatric conditions. Ayuh Ventures names the company in its selected portfolio. In October 2025, AbbVie completed the acquisition of Gilgamesh's bretisilocin asset. That transaction should not be described as acquisition of every Gilgamesh program: the company continues to describe other neuropsychiatric development programs on its website. Ayuh's current ownership and realized proceeds have not been disclosed here.

Why Gilgamesh Pharmaceuticals is interesting

Gilgamesh illustrates a biotech path from molecule development to a strategic pharmaceutical transaction. Distinguishing an asset acquisition from a whole-company acquisition is essential when interpreting the company's history and its investors' outcomes.

Product & use cases

The company describes a pipeline of novel chemical entities and neuropsychiatric programs. Bretisilocin, also known as GM-2505, was the subject of AbbVie's completed acquisition. Other programs and subsequent financing should be evaluated separately from the historical Ayuh relationship.

  • Development of investigational neuropsychiatric therapies.
  • Clinical research and pharmaceutical development partnerships.

Key facts

  • Named on Ayuh Ventures' official website.
  • AbbVie completed its bretisilocin asset acquisition on October 17, 2025.
  • No realized return or current Ayuh ownership percentage is inferred from the transaction.

Investors in our directory

Funds linked from Gilgamesh Pharmaceuticals's profile — open a fund page for stage focus and related deal articles.

Industries

Market / IPO context

Editorial / static context — not a live quote.

FAQs about Gilgamesh Pharmaceuticals

Practical answers founders, operators, and investors typically search for.

AbbVie's October 17, 2025 completion announcement identifies the acquired asset as bretisilocin. It should not be treated as evidence that every Gilgamesh program was acquired.
Ayuh's official website names Gilgamesh Pharmaceuticals. That establishes the disclosed portfolio relationship, not current ownership or a particular later financing.
AbbVie's completion announcement is at https://news.abbvie.com/2025-10-17-AbbVie-Completes-Acquisition-of-Gilgamesh-Pharmaceuticals-Bretisilocin.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.